Published in Retrovirology on March 20, 2007
HIV-1 drug resistance mutations: an updated framework for the second decade of HAART. AIDS Rev (2008) 2.88
Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137). J Virol (2007) 2.33
Structure-based modeling of the functional HIV-1 intasome and its inhibition. Proc Natl Acad Sci U S A (2010) 2.16
Human cellular restriction factors that target HIV-1 replication. BMC Med (2009) 1.86
Resistance mutations in human immunodeficiency virus type 1 integrase selected with elvitegravir confer reduced susceptibility to a wide range of integrase inhibitors. J Virol (2008) 1.83
Natural variation of HIV-1 group M integrase: implications for a new class of antiretroviral inhibitors. Retrovirology (2008) 1.79
"Shock and kill" effects of class I-selective histone deacetylase inhibitors in combination with the glutathione synthesis inhibitor buthionine sulfoximine in cell line models for HIV-1 quiescence. Retrovirology (2009) 1.59
Nuclear landscape of HIV-1 infection and integration. Nat Rev Microbiol (2016) 1.41
Piecing together the structure of retroviral integrase, an important target in AIDS therapy. FEBS J (2009) 1.27
Analysis of natural sequence variation and covariation in human immunodeficiency virus type 1 integrase. J Virol (2008) 1.27
Response of a simian immunodeficiency virus (SIVmac251) to raltegravir: a basis for a new treatment for simian AIDS and an animal model for studying lentiviral persistence during antiretroviral therapy. Retrovirology (2010) 1.13
Comparative biochemical analysis of HIV-1 subtype B and C integrase enzymes. Retrovirology (2009) 1.05
Targeting the transposase domain of the DNA repair component Metnase to enhance chemotherapy. Cancer Res (2012) 1.01
A dynamic model of HIV integrase inhibition and drug resistance. J Mol Biol (2010) 0.99
Molecular dynamics approaches estimate the binding energy of HIV-1 integrase inhibitors and correlate with in vitro activity. Antimicrob Agents Chemother (2011) 0.97
Human immunodeficiency virus integrase inhibitors efficiently suppress feline immunodeficiency virus replication in vitro and provide a rationale to redesign antiretroviral treatment for feline AIDS. Retrovirology (2007) 0.95
Polymorphisms of HIV-2 integrase and selection of resistance to raltegravir. Retrovirology (2010) 0.90
Structure-analysis of the HIV-1 integrase Y143C/R raltegravir resistance mutation in association with the secondary mutation T97A. Antimicrob Agents Chemother (2011) 0.87
The Retrovirology Open Access experience. Retrovirology (2009) 0.86
Characterization of the HIV-1 integrase chromatin- and LEDGF/p75-binding abilities by mutagenic analysis within the catalytic core domain of integrase. Virol J (2010) 0.86
Receptor independent and receptor dependent CoMSA modeling with IVE-PLS: application to CBG benchmark steroids and reductase activators. J Mol Model (2008) 0.80
Exploring the binding of HIV-1 integrase inhibitors by comparative residue interaction analysis (CoRIA). J Mol Model (2008) 0.80
Design, Synthesis, and Biological Evaluation of 1,2-Dihydroisoquinolines as HIV-1 Integrase Inhibitors. ACS Med Chem Lett (2015) 0.78
Computer tools in the discovery of HIV-1 integrase inhibitors. Future Med Chem (2010) 0.77
Emerging role of integrase inhibitors in the management of treatment-experienced patients with HIV infection. Ther Clin Risk Manag (2009) 0.76
Please comment, but with civility. Retrovirology (2008) 0.75
Anti-HIV drug development through computational methods. AAPS J (2014) 0.75
Development and validation of a genetic algorithm for flexible docking. J Mol Biol (1997) 14.36
Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science (2000) 7.01
Crystal structures of RNase H bound to an RNA/DNA hybrid: substrate specificity and metal-dependent catalysis. Cell (2005) 5.43
Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals. J Acquir Immune Defic Syndr (2006) 4.71
Integrase inhibitors to treat HIV/AIDS. Nat Rev Drug Discov (2005) 4.46
Three-dimensional structure of the Tn5 synaptic complex transposition intermediate. Science (2000) 4.00
Diketo acid inhibitor mechanism and HIV-1 integrase: implications for metal binding in the active site of phosphotransferase enzymes. Proc Natl Acad Sci U S A (2002) 3.40
Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatment-naive and treatment-experienced patients. J Acquir Immune Defic Syndr (2006) 3.24
Structure of a two-domain fragment of HIV-1 integrase: implications for domain organization in the intact protein. EMBO J (2001) 3.23
Structural basis for the recognition between HIV-1 integrase and transcriptional coactivator p75. Proc Natl Acad Sci U S A (2005) 3.18
HIV-1 integrase inhibitors that compete with the target DNA substrate define a unique strand transfer conformation for integrase. Proc Natl Acad Sci U S A (2000) 3.00
Sequence specificity of viral end DNA binding by HIV-1 integrase reveals critical regions for protein-DNA interaction. EMBO J (1998) 2.84
Structure of the HIV-1 integrase catalytic domain complexed with an inhibitor: a platform for antiviral drug design. Proc Natl Acad Sci U S A (1999) 2.69
A naphthyridine carboxamide provides evidence for discordant resistance between mechanistically identical inhibitors of HIV-1 integrase. Proc Natl Acad Sci U S A (2004) 2.55
Crystal structures of the catalytic domain of HIV-1 integrase free and complexed with its metal cofactor: high level of similarity of the active site with other viral integrases. J Mol Biol (1998) 2.49
Recombining the structures of HIV integrase, RuvC and RNase H. Structure (1995) 2.48
Stepwise analyses of metal ions in RNase H catalysis from substrate destabilization to product release. EMBO J (2006) 2.23
Integrase inhibitors and cellular immunity suppress retroviral replication in rhesus macaques. Science (2004) 2.12
A new test set for validating predictions of protein-ligand interaction. Proteins (2002) 2.08
Tn10 transposition via a DNA hairpin intermediate. Cell (1998) 2.05
Novel HIV-1 integrase inhibitors derived from quinolone antibiotics. J Med Chem (2006) 2.03
Comparative architecture of transposase and integrase complexes. Nat Struct Biol (2001) 1.99
Inhibition of HIV-1 ribonuclease H by a novel diketo acid, 4-[5-(benzoylamino)thien-2-yl]-2,4-dioxobutanoic acid. J Biol Chem (2002) 1.80
In vivo evidence for instability of episomal human immunodeficiency virus type 1 cDNA. J Virol (2005) 1.80
Binding of different divalent cations to the active site of avian sarcoma virus integrase and their effects on enzymatic activity. J Biol Chem (1997) 1.47
Multiple mutations in human immunodeficiency virus-1 integrase confer resistance to the clinical trial drug S-1360. AIDS (2004) 1.28
Isolation and characterization of novel human immunodeficiency virus integrase inhibitors from fungal metabolites. Antivir Chem Chemother (1999) 1.23
NMR structure of the Tn916 integrase-DNA complex. Nat Struct Biol (1999) 1.23
A historical sketch of the discovery and development of HIV-1 integrase inhibitors. Expert Opin Investig Drugs (2006) 1.22
Prediction of HIV-1 integrase/viral DNA interactions in the catalytic domain by fast molecular docking. J Med Chem (2004) 1.04
Molecular dynamics studies of the full-length integrase-DNA complex. Biochem Biophys Res Commun (2005) 1.03
Probing HIV-1 integrase inhibitor binding sites with position-specific integrase-DNA cross-linking assays. Mol Pharmacol (2006) 1.03
Preliminary mapping of a putative inhibitor-binding pocket for human immunodeficiency virus type 1 integrase inhibitors. Antimicrob Agents Chemother (2006) 1.02
4,5-dihydroxypyrimidine carboxamides and N-alkyl-5-hydroxypyrimidinone carboxamides are potent, selective HIV integrase inhibitors with good pharmacokinetic profiles in preclinical species. J Med Chem (2006) 0.94
Development of integrase inhibitors for treatment of AIDS: an overview. Eur J Med Chem (2007) 0.90
Design and synthesis of novel N-sulfonyl-2-indole carboxamides as potent PPAR-gamma binding agents with potential application to the treatment of osteoporosis. Bioorg Med Chem Lett (2006) 0.90
HIV nuclear import: What's the flap? Nat Med (2000) 0.89
Novel HIV integrase inhibitors with anti-HIV activity: insights into integrase inhibition from docking studies. Antivir Chem Chemother (2006) 0.88
Binding mode prediction of strand transfer HIV-1 integrase inhibitors using Tn5 transposase as a plausible surrogate model for HIV-1 integrase. J Med Chem (2006) 0.87
SAR and factor IXa crystal structure of a dual inhibitor of factors IXa and Xa. Bioorg Med Chem Lett (2004) 0.84